Oswaldo Cruz Foundation   Report issue

Foundation Phase 1 Phase 2 Phase 3 Phase 4
Founded: Rio de Janeiro Brazil (1898)

Organization Overview

First Clinical Trial
2006
NCT00303082
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Ana Rabello | Argentina: FIPEC Foundation (Fundación para el Estudio de las Infecciones Parasitarias y Enfermedad de Chagas | Evandro Chagas Institute of Clinical Research | Evandro Chagas National Institute of Infectious Disease | Fiocruz, Rio de Janiero, Brazil | Fundacao Oswaldo Cruz | Hospital Alemão Oswaldo Cruz | Instituto de pesquisa Clinica Evandro Chagas | Instituto de Pesquisa Clinica Evandro Chagas-Fiocruz | Instituto de Pesquisa Clinica Evandro Chagas, Fiocruz | Instituto Oswaldo Cruz | Instituto Oswaldo Cruz, Fiocruz | International Research Center - Hospital Alemão Oswaldo Cruz | IPEC - Oswaldo Cruz Foundation | Laboratory on Clinical research on DST/AIDS-IPEC FIOCRUZ Av Brasil, 4365 Manguinhos Rio de Janeiro, Brazil CEP 21040-900 | Oswaldo Cruz Foundation | Oswaldo Cruz Institute | Oswaldo Cruz Institute, Oswaldo Cruz Foundation | Plataforma de Antención Integral de Pacientes con Enfermedad de Chagas, Cochabamba, Bolivia | Plataforma de Antención Integral de Pacientes con Enfermedad de Chagas, Tarija, Bolivia | Plataforma de Atención Integral de Pacientes con Enfermedad de Chagas. Cochabamba, Bolivia. | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)

Active Ingredients

Drugs in Phase 4 Trials (27)

apixaban (eliquis) (1 trial)

bacille calmette-guerin (2 trials)

benznidazole (Rochagan) (2 trials)

bnt162b2 (Comirnaty) (1 trial)

chadox1 (2 trials)

darunavir (prezista) (1 trial)

efavirenz (sustiva) (3 trials)

emtricitabine (emtriva) (3 trials)

enoxaparin (lovenox) (1 trial)

etravirine (intelence) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

immune globulin (human) (Gamastan) (1 trial)

interferon alpha-2b (Intron-A) (3 trials)

isoniazid (nydrazid) (2 trials)

lopinavir (Kaletra) (3 trials)

measles, mumps, and rubella vaccine (MMR) (2 trials)

mebendazole (vermox) (1 trial)

nvx-cov2373 (Covovax) (2 trials)

praziquantel (biltricide) (1 trial)

raltegravir (isentress) (3 trials)

ribavirin (virazole) (1 trial)

ritonavir (Norvir) (3 trials)

rivaroxaban (xarelto) (2 trials)

sodium chloride (1 trial)

tenofovir (viread) (4 trials)

unfractionated heparin (1 trial)

yellow fever vaccine 17d strain (2 trials)

Drugs in Phase 3 Trials (25)

antimony (2 trials)

artesunate (1 trial)

azithromycin (zithromax) (1 trial)

cabotegravir (Vocabria) (1 trial)

chlorhexidine (hibitane) (1 trial)

chloroquine (3 trials)

dihydroartemisinin (1 trial)

epidermal growth factor (1 trial)

epoetin (Epogen) (1 trial)

lactobacillus reuteri (1 trial)

lactobacillus rhamnosus (1 trial)

lamivudine (epivir) (1 trial)

measles-rubella vaccine (M-R-Vax) (1 trial)

mefloquine (lariam) (1 trial)

meglumine (2 trials)

methylglucamine antimoniate (1 trial)

miltefosine (impavido) (1 trial)

Monovalent group C meningococcal vaccine (Menomune-C) (1 trial)

piperaquine (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (2 trials)

primaquine (4 trials)

sargramostim (leukine) (1 trial)

selenium (1 trial)

tecovirimat (tpoxx) (1 trial)

tocilizumab (actemra) (1 trial)

Drugs in Phase 2 Trials (11)

18-methoxycoronaridine (1 trial)

allogeneic adipose derived mesenchymal stem cell (2 trials)

autologous extracellular vesicles from serum (1 trial)

bone marrow derived mesenchymal stem cells (1 trial)

e1224 (1 trial)

fexinidazole (1 trial)

gla-se (5 trials)

inactivated influenza vaccine (1 trial)

lep-f1 (1 trial)

sm14 vaccine (4 trials)

sm29 (1 trial)

Drugs in Phase 1 Trials (6)

attenuated measles vaccine - Edmonston strain (rubeovax) (1 trial)

autologous mononuclear stem cell (1 trial)

icosapent ethyl (vascepa) (1 trial)

na-asp-2 (1 trial)

quadrivalent groups a, c, y, and w-135 meningococcal vaccine (Menomune-A/C/Y/W-135) (1 trial)

rubella virus vaccine live (Meruvax) (1 trial)

Drugs in Other Trials (7)

brazil nut (1 trial)

coartem (1 trial)

fluorouracil (efudex) (1 trial)

lumefantrine (Coartem) (1 trial)

methotrexate (1 trial)

oxaliplatin (eloxatin) (1 trial)

prednisolone (hydeltra) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ancylostomiasis (Phase 1)

Anemia, Sickle Cell (Phase 2)

Bronchopulmonary Dysplasia (Phase 3)

Cardiomyopathies (Phase 1)

Chagas Cardiomyopathy (Phase 1)

Chagas Disease (Phase 4)

Coronavirus Infections (Phase 4)

Diabetic Foot (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Erythroblastosis, Fetal (Phase 4)

Fever (Phase 4)

Fibrosis (Phase 1)

Foot Ulcer (Phase 3)

Glucosephosphate Dehydrogenase Deficiency (Phase 2)

Heart Diseases (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

Hepatitis, Chronic (Phase 3)

HIV Infections (Phase 4)

Hookworm Infections (Phase 1)

Hyperbilirubinemia (Phase 4)

Influenza, Human (Phase 2)

Kidney Failure, Chronic (Phase 3)

Leg Ulcer (Phase 1)

Leishmaniasis (Phase 3)

Leishmaniasis, Cutaneous (Phase 3)

Leishmaniasis, Mucocutaneous (Phase 3)

Leprosy (Phase 2)

Leukomalacia, Periventricular (Phase 3)

Liver Cirrhosis (Phase 1)

Malaria (Phase 3)

Malaria, Falciparum (Phase 3)

Malaria, Vivax (Phase 3)

Measles (Phase 4)

Meningitis (Phase 3)

Meningitis, Meningococcal (Phase 3)

Mumps (Phase 4)

Necrosis (Phase 2)

Osteonecrosis (Phase 2)

Pneumonia (Phase 3)

Premature Birth (Phase 3)

Rubella (Phase 4)

Schistosomiasis (Phase 4)

Schistosomiasis mansoni (Phase 4)

Severe Acute Respiratory Syndrome (Phase 4)

Skin Ulcer (Phase 1)

Trypanosomiasis (Phase 2)

Tuberculosis (Phase 4)

Tuberculosis, Pulmonary (Phase 4)

Ulcer (Phase 3)

Vaginal Diseases (Phase 3)

Vaginosis, Bacterial (Phase 3)

Yellow Fever (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 75
  • # of Trial APIs: 76